All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Krina Patel, MD Anderson Cancer Center, Houston, US. We asked, How might intravenous immunoglobulin therapy (IVIG) therapy be used to treat infection after B-cell maturation antigen (BCMA)-targeted therapies in MM?
How might IVIG therapy be used to treat infection after BCMA-targeted therapies in MM?
In this interview Krina Patel opens by explaining how BCMA-targeted therapies, used to treat MM, can result in a higher rate of infection. Patel then goes on to explain the applications of IVIG to treat these infections, outlining which patients the treatment is most appropriate for, as well as the recommended dosing regimens. Patel concludes by discussing alternative methods for prophylaxis and treatment of infections in MM.
ASH 2022: Top abstracts in MM and other plasma cell dyscrasias
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members...
EHA2022 abstracts: What's hot in multiple myeloma?
To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look...
Subscribe to get the best content related to multiple myeloma delivered to your inbox